Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | CDC42 | P60953 | 1/20 | 0.39 |
| ▸ | RAC1 | P63000 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229950 | 0.83 | PTGS2 (0.40) | MTNR1AMTNR1BPTGS2AKR1C3AKR1C2 | |
| SCHEMBL1723874 | 0.78 | MTNR1A (0.36) | MTNR1AMTNR1BTSHRPOLBTDP1 | |
| SCHEMBL3149015 | 0.75 | MTNR1A (0.41) | MTNR1AMTNR1BPTGS2AKR1C3AKR1C2 | |
| SCHEMBL3400408 | 0.72 | POLB (0.40) | MTNR1AMTNR1BPTGS2POLBTDP1 | |
| SCHEMBL1712054 | 0.72 | MTNR1A (0.38) | MTNR1AMTNR1BHTR2C | |
| SCHEMBL1712055 | 0.72 | MTNR1A (0.40) | MTNR1AMTNR1BHTR2C | |
| SCHEMBL1712179 | 0.71 | MTNR1A (0.39) | MTNR1AMTNR1BPTGS2POLBTDP1 | |
| SCHEMBL4430363 | 0.71 | MTNR1A (0.42) | MTNR1AMTNR1BPOLBTDP1HTR2C | |
| SCHEMBL3220236 | 0.70 | POLB (0.38) | MTNR1AMTNR1BPTGS2POLBTDP1 | |
| SCHEMBL1712093 | 0.70 | MTNR1A (0.31) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | MTNR1A 3542/4885MTNR1B 3214/4885PTGS2 1492/4885 |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | MTNR1A 1695/4885MTNR1B 1409/4885PTGS2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.